Image

Evaluate the Performance of the Dexcom G7 Continuous Glucose Monitoring (CGM) System in Critically Ill Patients Undergoing Major Abdominal Surgery and Solid Organ Transplantation Which Require Blood Glucose Monitoring for Intensive Insulin Therapy.

Evaluate the Performance of the Dexcom G7 Continuous Glucose Monitoring (CGM) System in Critically Ill Patients Undergoing Major Abdominal Surgery and Solid Organ Transplantation Which Require Blood Glucose Monitoring for Intensive Insulin Therapy.

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Main objective:

The goal is to to determine the accuracy of Dexcom G7 Continuous glucose monitor system in critically ill patients, undergoing major abdominal surgery and solid organ transplantation, in the intensive care unit.

On admission to the intensive care unit or at the end of surgery, two Dexcom G7 sensors are placed in the infraclavicular position.

Sensor number 1 will be blinded and will only be active when paired with the receiver, without the ability to monitor glucose levels.

Sensor number 2 is used for continuous glucose monitoring and can be used to adjust the insulin dose.

Patients will wear the continuous glucose monitoring sensor for a maximum of 10 days, including the time spent in the intensive care unit and the immediate care unit. The study will not interfere with any usual care clinical workflows.

Calibration is only performed on an unblinded sensor. The reference method for calibration is the glucose from the blood glucose meter.

Calibrate on the first day of monitoring: 4 times a day after approximately 6 hours, or if the blood glucose reading from the blood glucose meter is not within the estimated error range of the continuous glucose monitor (difference greater than 1,5mmol/L).

Calibration on days 2 and 3 of monitoring: once in the morning, or when the meter's glucose reading is not within the estimated error range of the continuous glucose monitoring (difference greater than 1,5mmol/L) On subsequent days when the blood glucose meter reading is not within the estimated error range of continuous glucose monitoring (difference greater than 1,5mmol/L).

Hypothesis
  • Ho: No difference in mean absolute relative difference (MARD) between calibrated and non-calibrated sensors.
  • Ha: Calibrated sensors have lower mean absolute relative difference (δ = 4%, SD = 5%).

Further objectives:

To evaluate further aspects regarding the Dexcom G7 continuous glucose monitor system's performance in the intensive care unit (ICU), particularly in terms of sensitivity and specificity to detect hypo- and hyperglycaemic events, data availability, device deficiencies and safety.

To identify predictive factors of the accuracy of the Dexcom G7 continuous glucose monitor system in critically ill patients in the ICU.

Description

Design
  • Each intensive care unit patient wears two sensors (calibrated + non-calibrated).
  • 4 glucose measurements/day × 6 days = 24 measurements/subject.
  • Sequential Organ Failure Assessment (SOFA) score recorded daily.

Eligibility

Inclusion Criteria:

  • Age 18 years or over
  • Intensive care unit admission
  • Requiring blood glucose monitoring for insulin therapy

Exclusion Criteria:

  • High-dose ascorbic acid or acetaminophen \> 4g/day
  • Physical or mental health condition precluding continuous wear of the continuous glucose monitor, as judged by the physician

Study details
    CGM
    Intensive Care (ICU)
    Liver Transplant Surgery
    Solid Organ Transplantation
    Major Abdominal Surgeries
    Diabetes (Insulin-requiring
    Type 1 or Type 2)

NCT07611721

Institute for Clinical and Experimental Medicine

27 June 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.